The risk of various types of cardiovascular diseases in mutation positive familial hypercholesterolemia; a review

被引:4
作者
Hovland, Anders [1 ]
Mundal, Liv J. [2 ]
Veierod, Marit B. [3 ]
Holven, Kirsten B. [4 ,5 ]
Bogsrud, Martin Proven [6 ]
Tell, Grethe S. [7 ,8 ]
Leren, Trond P. [6 ]
Retterstol, Kjetil [2 ,4 ]
机构
[1] Nordland Heart Ctr, Bodo, Norway
[2] Oslo Univ Hosp, Lipid Clin, Oslo, Norway
[3] Univ Oslo, Oslo Ctr Biostat & Epidemiol, Dept Biostat, Oslo, Norway
[4] Univ Oslo, Dept Nutr, Oslo, Norway
[5] Oslo Univ Hosp, Natl Advisory Unit Familial Hypercholesterolemia, Oslo, Norway
[6] Oslo Univ Hosp, Unit Cardiac & Cardiovasc Genet, Oslo, Norway
[7] Univ Bergen, Dept Global Publ Hlth & Primary Care, Bergen, Norway
[8] Div Mental, Bergen, Norway
关键词
familial hypecholesterolemia; ASCVD; LDL; cholesterol; statin (HMG-CoA reductase inhibitor); aortic valve stenosis; stroke; myocardial infaction; PERIPHERAL ARTERIAL-DISEASE; RECEPTOR MUTATION; PREVALENCE; INSIGHTS; NORWAY; SCORE; TIME;
D O I
10.3389/fgene.2022.1072108
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Familial hypercholesterolemia (FH) is a common, inherited disease characterized by high levels of low-density lipoprotein Cholesterol (LDL-C) from birth. Any diseases associated with increased LDL-C levels including atherosclerotic cardiovascular diseases (ASCVDs) would be expected to be overrepresented among FH patients. There are several clinical scoring systems aiming to diagnose FH, however; most individuals who meet the clinical criteria for a FH diagnosis do not have a mutation causing FH. In this review, we aim to summarize the literature on the risk for the various forms of ASCVD in subjects with a proven FH-mutation (FH+). We searched for studies on FH+ and cardiovascular diseases and also included our and other groups published papers on FH + on a wide range of cardiovascular and other diseases of the heart and vessels. FH + patients are at a markedly increased risk of a broad range of ASCVD. Acute myocardial infarction (AMI) is the most common in absolute numbers, but also aortic valve stenosis is by far associated with the highest excess risk. Per thousand patients, we observed 3.6 incident AMI per year compared to 1.9 incident aortic valve stenosis, however, standardized incidence ratio (SIR) for incident AMI was 2.3 compared to 7.9 for incident aortic valve stenosis. Further, occurrence of ischemic stroke seems not to be associated with increased risk in FH+. Clinicians should be aware of the excess risk of almost all kind of ASCVD in FH+, and the neutral risk of stroke need to be studied further in FH + patients.
引用
收藏
页数:8
相关论文
共 49 条
  • [1] Clinical and molecular characteristics of homozygous familial hypercholesterolemia patients: Insights from SAFEHEART registry
    Alonso, Rodrigo
    Luis Diaz-Diaz, Jose
    Arrieta, Francisco
    Fuentes-Jimenez, Francisco
    de Andres, Raimundo
    Saenz, Pedro
    Ariceta, Gema
    Vidal-Pardo, Jose I.
    Almagro, Fatima
    Argueso, Rosa
    Prieto-Matos, Pablo
    Miramontes, Jose P.
    Pinto, Xavier
    Rodriguez-Urrego, Johana
    Perez de Isla, Leopoldo
    Mata, Pedro
    [J]. JOURNAL OF CLINICAL LIPIDOLOGY, 2016, 10 (04) : 953 - 961
  • [2] Lipoprotein(a) Levels in Familial Hypercholesterolemia An Important Predictor of Cardiovascular Disease Independent of the Type of LDL Receptor Mutation
    Alonso, Rodrigo
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2014, 63 (19) : 1983 - 1989
  • [3] Genetically Confirmed Familial Hypercholesterolemia in Patients With Acute Coronary Syndrome
    Amor-Salamanca, Almudena
    Castillo, Sergio
    Gonzalez-Vioque, Emiliano
    Dominguez, Fernando
    Quintana, Lucia
    Lluis-Ganella, Carla
    Manuel Escudier, Juan
    Ortega, Javier
    Lara-Pezzi, Enrique
    Alonso-Pulpon, Luis
    Garcia-Pavia, Pablo
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2017, 70 (14) : 1732 - 1740
  • [4] [Anonymous], 1991, BMJ, V303, P893
  • [5] Risk of Recurrent Coronary Events in Patients With Familial Hypercholesterolemia; A 10-Years Prospective Study
    Arnesen, Kjell-Erik
    Phung, Ann Vinh
    Randsborg, Karoline
    Mork, Irene
    Thorvall, Marlene
    Langslet, Gisle
    Svilaas, Arne
    Wium, Cecilie
    Ose, Leiv
    Retterstol, Kjetil
    [J]. FRONTIERS IN PHARMACOLOGY, 2021, 11
  • [6] Characteristics and trends of PCSK9 inhibitor prescription fills in the United States
    Attipoe-Dorcoo, Sharon
    Yang, Peter
    Sperling, Laurence
    Loustalot, Fleetwood
    Thompson-Paul, Angela M.
    Gray, Elizabeth B.
    Park, Soyoun
    Ritchey, Matthew D.
    [J]. JOURNAL OF CLINICAL LIPIDOLOGY, 2021, 15 (02) : 332 - 338
  • [7] Relationship of Familial Hypercholesterolemia and High Low-Density Lipoprotein Cholesterol to Ischemic Stroke: Copenhagen General Population Study
    Beheshti, Sabina
    Madsen, Christian M.
    Varbo, Anette
    Benn, Marianne
    Nordestgaard, Borge G.
    [J]. CIRCULATION, 2018, 138 (06) : 578 - 589
  • [8] Severe heterozygous familial hypercholesterolemia and risk for cardiovascular disease: A study of a cohort of 14,000 mutation carriers
    Besseling, Joost
    Kindt, Iris
    Hof, Michel
    Kastelein, John J. P.
    Hutten, Barbara A.
    Hovingh, G. Kees
    [J]. ATHEROSCLEROSIS, 2014, 233 (01) : 219 - 223
  • [9] Betteridge J.D., 2000, LIPIDS VASCULAR DIS
  • [10] Prevalence of genetically verified familial hypercholesterolemia among young (<45 years) Norwegian patients hospitalized with acute myocardial infarction
    Bogsrud, Martin P.
    Oyri, Linn K. L.
    Halvorsen, Sigrun
    Atar, Dan
    Leren, Trond P.
    Holven, Kirsten B.
    [J]. JOURNAL OF CLINICAL LIPIDOLOGY, 2020, 14 (03) : 339 - 345